== Adverse effects ==

 
Very common (greater than 10% of people experience them) adverse effects include upper respiratory tract infections

 
Secukinumab was discovered and developed by Novartis using developmental name AIN457, and the first publication was a Phase I trial published in 2010.<ref>{{cite journal|last1=Nelson|first1=AL|last2=Dhimolea|first2=E|last3=Reichert|first3=JM|title=Development trends for human monoclonal antibody therapeutics.|journal=Nature reviews. Drug discovery|date=October 2010|volume=9|issue=10|pages=767-74|doi=10.1038/nrd3229|pmid=20811384}}</ref><ref>{{cite journal|last1=Hueber|first1=W|last2=Patel|first2=DD|last3=Dryja|first3=T|last4=Wright|first4=AM|last5=Koroleva|first5=I|last6=Bruin|first6=G|last7=Antoni|first7=C|last8=Draelos|first8=Z|last9=Gold|first9=MH|last10=Psoriasis Study|first10=Group.|last11=Durez|first11=P|last12=Tak|first12=PP|last13=Gomez-Reino|first13=JJ|last14=Rheumatoid Arthritis Study|first14=Group.|last15=Foster|first15=CS|last16=Kim|first16=RY|last17=Samson|first17=CM|last18=Falk|first18=NS|last19=Chu|first19=DS|last20=Callanan|first20=D|last21=Nguyen|first21=QD|last22=Uveitis Study|first22=Group.|last23=Rose|first23=K|last24=Haider|first24=A|last25=Di Padova|first25=F|title=Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.|journal=Science translational medicine|date=6 October 2010|volume=2|issue=52|pages=52ra72|doi=10.1126/scitranslmed.3001107|pmid=20926833|url=http://stm.sciencemag.org/content/2/52/52ra72.full}}</ref><ref>{{cite news|title=Novartis Snags Remaining 23% Stake in Alcon with $12.9B Cash and Share Deal|url=http://www.genengnews.com/gen-news-highlights/novartis-snags-remaining-23-stake-in-alcon-with-12-9b-cash-and-share-deal/81244384|work=Genetic Engineering News|date=December 15, 2010}}</ref><ref>{{cite web|last1=Padova|first1=Franco E. Di|last2=Gram|first2=Hermann|last3=Hofstetter|first3=Hans|last4=Jeschke|first4=Margit|last5=Rondeau|first5=Jean-Michel|last6=Berg|first6=Wim Van Den|title=US 7807155: IL-17 antagonistic antibodies|url=https://www.google.com/patents/US7807155|date=2010}}</ref>
